title: [Mycobacterial species repartition: experience of the Antituberculosis Center in Pointe Noire (Republic of Congo)].
abstract: The aim of the present work was to describe mycobacteria species isolated in the antituberculosis center of Pointe-Noire city in Congo Brazzaville. It was a descriptive transversal study, conducted between September 2008 and April 2009 (7 months). A simple random sample was established from patients who came to the antituberculosis center of Pointe-Noire City (reference center on diagnosis and treatment of tuberculosis). To those patients consulting with symptoms leading to suspect pulmonary tuberculosis, a sputum sampling in three sessions was conducted. Staining techniques to Ziehl-Neelsen and auramine were performed in Pointe-Noire. Culture, molecular hybridization and antibiotic susceptibility testing to first-line antituberculosis drugs (isoniazid, rifampicin, ethambutol, pyrazinamide or streptomycine) using diffusion method on agar were performed in Cerba Pasteur laboratory in France. In 77 patients, 24 sputum (31.20%) were positive to the microscopic examination and 45 (58.44%) to the culture and identification by molecular hybridization. Mycobacteria species complex isolated were M. tuberculosis with 31 cases (68.9%) and M. africanum with 3 cases (6.67%). Non-tuberculous mycobacteria (NMT) were isolated in association or not with M. tuberculosis in 9 cases (20%) and the most common species were M. intracellulare. In M. tuberculosis species, 7 strains (41.20%) were tested sensitive to the first-line antituberculosis drugs, 8 cases (47%) monoresistance and 2 cases multidrug resistance at both isoniazide and rifampicine (12%) (MDR). This study showed the importance of Mycobacteria species complex and non-mycobacteria species in pulmonary tuberculosis. The data on resistance can help medical physicians in the treatment of pulmonary tuberculosis. Another study with a large population is required to confirm these data.
authors.affiliation: Département de microbiologie et hématologie, Faculté des sciences de la santé de Brazzaville, Brazzaville, République du Congo, esther_muller2003@yahoo.fr.
authors.forename: E N
authors.initials: EN
authors.lastname: Ontsira Ngoyi
authors.lastname: Obengui
authors.forename: R
authors.initials: R
authors.lastname: Taty Taty
authors.forename: E L
authors.initials: EL
authors.lastname: Koumba
authors.forename: P
authors.initials: P
authors.lastname: Ngala
authors.forename: R B
authors.initials: RB
authors.lastname: Ossibi Ibara
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000382:microbiology; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use; D003223:Congo / Q000453:epidemiology; D003430:Cross-Sectional Studies; D024901:Drug Resistance, Multiple, Bacterial; D015658:HIV Infections / Q000150:complications; D006763:Hospitals, Chronic Disease; D006801:Humans; D009161:Mycobacterium / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification*; D009164:Mycobacterium Infections / Q000382:microbiology*; D009165:Mycobacterium Infections, Nontuberculous / Q000382:microbiology; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D012494:Sampling Studies; D014376:Tuberculosis / Q000150:complications / Q000382:microbiology*; D018088:Tuberculosis, Multidrug-Resistant / Q000453:epidemiology / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents